Epigenetics Drives Pharma Innovation - Therapeutics targeting epigenetic mechanisms of disease will change the pharmaceutical marketplace. - BioPharm International

ADVERTISEMENT

Epigenetics Drives Pharma Innovation
Therapeutics targeting epigenetic mechanisms of disease will change the pharmaceutical marketplace.


BioPharm International
Volume 26, Issue 1, pp. 32-33

REFERENCES

1. M.E. Donohoe ME. Results Probl. Cell Differ. 55, 231–45 (2012).

2. K. Banno et al., Biochem. Res. Int. onlline, DOI :10.1155/2012/738274 738274, February, 2012.

3. Y. Boumber and J.P. Issa, Oncology 25 (3), 220–228 (2011).

4. P. Lopez-Serra and M. Esteller, Oncogene 31 (13), 1609–1622 (2012).

5. M. Esteller, N. Eng. J. Med. 358, 1148–1159 (2008).

6. P. Ao et al., Med. Hypotheses 70 (3), 678–684 (2008).

7. S.K. Bolta et al., Breast Cancer Res. Treat. 135 (3), 705–13 (2012).

8. Cai et al., Int. J. Mol. Sci. 12 (7), 4465–4487 (2012).

9. S.B. Baylin and P.A. Jones, Nat. Rev. Cancer 11 (10), 726–734 (2011).

10. M. Tessema et al., Carcinogenesis 30 (7), 1132–1138 (2009).

11. J.M Yingling JM, "The Changing Field of Drug Development," online Jul. 16, 2012. http://ecancer.org/tv/subject/611/1547/video.10 accessed Dec. 13, 2012.

12. P. Cuatrecasas, J. Clin. Invest. 116 (11), 2837–2842 (2006).

13. T. Kubota, K. Miyake, and T. Hirasawa, Clin. Epigenetics 4 (1), 1 (2012).

14. K.J. Morrow, Kalorama Reports, Pub ID: KLI3860511, pg. 160 (2012).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here